Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?

Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3.
No abstract available

Publication types

  • Comment

MeSH terms

  • Acrylamides
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung*
  • ErbB Receptors / genetics
  • Humans
  • Lung Neoplasms*
  • Mutation
  • Protein Kinase Inhibitors
  • Pyrazines
  • Triazines

Substances

  • 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
  • Acrylamides
  • Aniline Compounds
  • Protein Kinase Inhibitors
  • Pyrazines
  • Triazines
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors

Associated data

  • ClinicalTrials.gov/NCT03778229
  • ClinicalTrials.gov/NCT03944772